These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 18330027)

  • 1. [Myelodysplastic syndrome].
    Mitani K
    Nihon Rinsho; 2008 Mar; 66(3):513-9. PubMed ID: 18330027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The lower risk MDS patient at risk of rapid progression.
    Mittelman M; Oster HS; Hoffman M; Neumann D
    Leuk Res; 2010 Dec; 34(12):1551-5. PubMed ID: 20573398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. More is better: combination therapies for myelodysplastic syndromes.
    Ornstein MC; Mukherjee S; Sekeres MA
    Best Pract Res Clin Haematol; 2015 Mar; 28(1):22-31. PubMed ID: 25659727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myelodysplastic syndromes: biology and treatment.
    Jädersten M; Hellström-Lindberg E
    J Intern Med; 2009 Mar; 265(3):307-28. PubMed ID: 19141095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on the pharmacotherapy for myelodysplastic syndromes.
    Duong VH; Komrokji RS; List AF
    Expert Opin Pharmacother; 2014 Sep; 15(13):1811-25. PubMed ID: 25080144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenalidomide Treatment for Lower Risk Nondeletion 5q Myelodysplastic Syndromes Patients Yields Higher Response Rates When Used Before Azacitidine.
    Zeidan AM; Al Ali NH; Padron E; Lancet J; List A; Komrokji RS
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):705-10. PubMed ID: 26440749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The difficulty to define progression patterns in patients with early stage myelodysplastic syndromes and deletion 5q--new prognostic markers are needed.
    Kuendgen A
    Leuk Res; 2014 Mar; 38(3):287-8. PubMed ID: 24433864
    [No Abstract]   [Full Text] [Related]  

  • 8. Management of myelodysplastic syndromes in adults: guidelines from the Belgian Haematological Society.
    Meers S; Breems D; Bries G; Delforge M; Graux C; Ravoet C; Selleslag D; Noens L;
    Acta Clin Belg; 2013; 68(4):253-62. PubMed ID: 24455794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Myelodysplastic syndromes: therapeutic advances and promising future].
    Nomdedeu B
    Med Clin (Barc); 2008 Oct; 131(13):500-2. PubMed ID: 19007578
    [No Abstract]   [Full Text] [Related]  

  • 10. Lenalidomide: targeted anemia therapy for myelodysplastic syndromes.
    List AF; Baker AF; Green S; Bellamy W
    Cancer Control; 2006 Dec; 13 Suppl():4-11. PubMed ID: 17242661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide.
    Loiseau C; Ali A; Itzykson R
    Exp Hematol; 2015 Aug; 43(8):661-72. PubMed ID: 26123365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myelodysplastic syndrome: An update on diagnosis and therapy.
    Koppel A; Schiller G
    Curr Hematol Malig Rep; 2009 Jan; 4(1):10-6. PubMed ID: 20425433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
    Nimer SD
    J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in low- and intermediate-1-risk myelodysplastic syndrome: developing a consensus for optimal therapy.
    Stone R; Sekeres M; Garcia-Manero G; Lyons RM
    Clin Adv Hematol Oncol; 2008 Dec; 6(12):1-15. PubMed ID: 19385003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications.
    Stahl M; Zeidan AM
    Cancer; 2017 May; 123(10):1703-1713. PubMed ID: 28192601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
    Park S; Hamel JF; Toma A; Kelaidi C; Thépot S; Campelo MD; Santini V; Sekeres MA; Balleari E; Kaivers J; Sapena R; Götze K; Müller-Thomas C; Beyne-Rauzy O; Stamatoullas A; Kotsianidis I; Komrokji R; Steensma DP; Fensterl J; Roboz GJ; Bernal T; Ramos F; Calabuig M; Guerci-Bresler A; Bordessoule D; Cony-Makhoul P; Cheze S; Wattel E; Rose C; Vey N; Gioia D; Ferrero D; Gaidano G; Cametti G; Pane F; Sanna A; Germing U; Sanz GF; Dreyfus F; Fenaux P
    J Clin Oncol; 2017 May; 35(14):1591-1597. PubMed ID: 28350519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myelodysplastic syndromes (MDS).
    Klimek V
    Best Pract Res Clin Haematol; 2015 Mar; 28(1):1-2. PubMed ID: 25659724
    [No Abstract]   [Full Text] [Related]  

  • 18. [CME myelodysplasia - a frequent hematologic neoplasia in the elderly].
    Schleiffenbaum BE
    Praxis (Bern 1994); 2014 May; 103(11):617-27. PubMed ID: 24846886
    [No Abstract]   [Full Text] [Related]  

  • 19. Myelodysplasia: the good, the fair and the ugly.
    Schiffer CA
    Best Pract Res Clin Haematol; 2007 Mar; 20(1):49-55. PubMed ID: 17336254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of the association of lenalidomide to erythropoiesis-stimulating agents in del (5q) MDS patients refractory to single-agent lenalidomide.
    Park S; Vassilieff D; Bardet V; Viguié F; Dreyfus F
    Leukemia; 2010 Nov; 24(11):1960-2. PubMed ID: 20724986
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.